Wednesday, April 13, 2022

New trial results for patients with Relapsed/Refractory Large B-cell Lymphoma

New trial results for patients with Relapsed/Refractory Large B-cell Lymphoma - AbbVie and Genmab A/S today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy, including 38.9 percent who received prior treatment with chimeric antigen receptor (CAR) T-cell therapy. Based on the topline results, the companies will engage global regulatory authorities. LBCL is a fast-growing […] Click here to read: eTurboNews | TravelNews | World Talk
http://dlvr.it/SNXvBN

No comments:

Post a Comment